This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Another Look: Digging into Chimerix (CMRX) ONC-201 in recurrent H3 K27M-mutant glioma

Ticker(s): CMRX

Who's the expert?

Institution: UT Southwestern

  • Professor of Pediatric Hematology and Oncology & Medical Director of Pediatric neuro-oncology at Children's Health at University of Texas Southwestern.
  • Manages 15 patients a week with glioma and 4 patients for BRAF V600E-mutated low-grade glioma.
  • Research and clinical interests include the development of new therapies for children with brain tumors and cancer survivorship.

Interview Goal
Discuss potential of ONC-201 in treating glioma patients from a neuro-oncologist

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.